Data from University of California San Francisco (UCSF) Broaden Understanding of Cancer Gene Therapy (The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma).

Předmět:	LINCRNA CANCER genes GENE therapy CANCER treatment CELL survival
Zdroj:	Cancer Gene Therapy Week; 3/18/2024, p18-18, 1p
Abstrakt:	A recent study conducted at the University of California San Francisco (UCSF) has identified a long non-coding RNA (lncRNA) called T-RECS that is essential for the survival of cancer cells in NRAS/MAPK-driven melanoma. The researchers developed antisense oligonucleotides (ASOs) to target T-RECS and found that they reduced the growth of melanoma cells and induced cell death without affecting normal melanocytes. In mouse models, systemic treatment with T-RECS ASOs significantly suppressed the growth of melanoma tumors with no noticeable toxicity. This research suggests that ASO-mediated T-RECS inhibition could be a promising approach to improve the outcome of MAPK pathway-activated melanoma. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu